GRIFOLS’ PLASMA WORTH A SHOT (BUY; 27% UPSIDE)
17/09/20 -"Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma marketplace. While the FDA approval for the ..."
Pages
56
Language
English
Published on
17/09/20
You may also be interested by these reports :
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...